-
ISTH Guideline丨Latest ISTH Clinical Practice Guidelines for the Treatment of Hemophilia A and B Published
Hemophilia, a rare congenital bleeding disorder, is caused by pathogenic variants in the encoding genes, leading to the complete or partial deficiency of clotting factors VIII (Hemophilia A) or IX (Hemophilia B). Treating hemophilia involves certain complexities, and until now, no evidence-based clinical practice guidelines based on the GRADE methodology have been established to guide…
-
Exploring the Frontier and Building the Future: Dr. Tiejun Gong Discusses Standards and Innovations in Hematologic Oncology Treatment
The warm summer in Harbin was matched by a surge of medical wisdom. The 8th Hematology Academic Conference of the Chinese Society of Clinical Oncology (CSCO), hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held from July 26 to 28, 2024, in Harbin. This grand event brought together…
-
Dr. Huilai Zhang: Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma
Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and…
-
Dr. Huilai Zhang: Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma
Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and…
-
Dr. Jian Wu: Enhancing Public Awareness on Hepatitis E Prevention and Advancing Diagnosis and Treatment
July 28, 2024, marks the 14th World Hepatitis Day. Despite significant progress in combating viral hepatitis, it remains the most prevalent infectious disease in China. Hepatitis E (HEV) is particularly challenging, as China is a high-endemic region for the virus. To address the need for more standardized in-hospital screening procedures, accurate assessments, and a reduction…
-
Dr. Yuemin Nan: Strategies for the Prevention and Treatment of Metabolic Associated Fatty Liver Disease (MAFLD) and Lifestyle Adjustments
July 28 is “World Hepatitis Day,” and this year’s theme in China is “Eliminate Hepatitis: Act Now.” While the focus remains on viral hepatitis, the prevention and treatment of Metabolic Associated Fatty Liver Disease (MAFLD) should not be overlooked. In honor of World Hepatitis Day, Hepatology Digest invited Dr. Yuemin Nan from the Hebei Medical…
-
Dr. Jidong Jia: In-Depth Analysis of Hepatitis B and C Prevention Strategies, Building a Strong Defense Against Hepatitis
July 28, 2024, marks the 14th World Hepatitis Day. Recently, the National Disease Control and Prevention Administration released a report on the national legal infectious disease situation for May 2024, revealing that viral hepatitis remains the most prevalent category B infectious disease. In light of this, Hepatology Digest interviewed Dr. Jidong Jia from Beijing Friendship…
-
AIDS Exclusive Interview: Latest Advances and Challenges in Long-Acting HIV Prevention Technologies
At the AIDS 2024 Conference, Dr. Albert Liu from the University of California, San Francisco, delivered a keynote presentation on the latest developments in long-acting HIV prevention technologies. Following his talk, he participated in an exclusive interview with Infectious Diseases Frontier. Dr. Liu highlighted that the field of HIV prevention is currently undergoing exciting transformations.…
Connecting Medical Expertise through Media